亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and Efficacy of Upadacitinib in Crohn’s Disease: An Updated Systematic Review

医学 重症监护医学
作者
Aliu Olalekan Olatunji,Muhammad Furrakh Maqbool,Muhammad Abid,Karthik Sai Makineni,Mohammed Khaleel I Kh Almadhoun,Hamdah B Meer,Fazeela Ansari,Alma M Alfakhori,Adees Wirtan Sarkees Bedros,Nasreen Banu,Syed Faqeer Hussain Bokhari
出处
期刊:Cureus [Cureus, Inc.]
标识
DOI:10.7759/cureus.70125
摘要

Crohn's disease (CD) is a chronic inflammatory bowel disease that significantly impacts patient quality of life. This systematic review evaluates the safety and efficacy of upadacitinib, a selective Janus kinase (JAK) inhibitor, in the treatment of CD. A comprehensive literature search was conducted across multiple databases, yielding seven studies published between 2020 and 2024, encompassing 1,481 patients. The review includes randomized controlled trials, post hoc analyses of phase 3 trials, and observational studies. Findings consistently demonstrate upadacitinib's superiority over placebo in inducing and maintaining clinical remission, achieving endoscopic response, and normalizing inflammatory markers. Notably, upadacitinib showed rapid symptom relief, with clinical remission observed as early as five to six days after treatment initiation. Efficacy was observed across various patient populations, including those with prior biologic failure. Long-term studies indicated sustained clinical and endoscopic improvements, with remission rates maintained for up to 30 months. Upadacitinib also demonstrated effectiveness in real-world, treatment-refractory cohorts. Safety profiles were generally consistent with those of other JAK inhibitors. Common adverse events included infections, particularly herpes zoster, and laboratory abnormalities such as neutropenia and elevated creatine kinase. Serious adverse events were infrequent, although careful monitoring is warranted. This review suggests that upadacitinib is a promising treatment option for moderate to severe CD, offering rapid and sustained efficacy with an acceptable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI

祝大家在新的一年里科研腾飞
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lll完成签到 ,获得积分10
9秒前
13秒前
14秒前
lone623完成签到 ,获得积分10
19秒前
Vincent24S发布了新的文献求助10
19秒前
22秒前
Hermen发布了新的文献求助10
27秒前
燚龘完成签到,获得积分10
30秒前
不远完成签到,获得积分10
33秒前
燚龘发布了新的文献求助10
35秒前
Hermen完成签到,获得积分10
39秒前
完美世界应助科研通管家采纳,获得10
44秒前
44秒前
科研通AI2S应助科研通管家采纳,获得10
44秒前
Princessshark应助科研通管家采纳,获得10
44秒前
科研通AI2S应助科研通管家采纳,获得10
44秒前
香蕉觅云应助科研通管家采纳,获得10
44秒前
共享精神应助科研通管家采纳,获得10
44秒前
44秒前
51秒前
56秒前
1分钟前
大个应助燚龘采纳,获得10
1分钟前
nannan完成签到,获得积分10
1分钟前
1分钟前
Willer完成签到,获得积分10
1分钟前
zlx完成签到 ,获得积分10
1分钟前
可爱的函函应助nannan采纳,获得10
1分钟前
傅英俊发布了新的文献求助10
1分钟前
西陆完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
修语发布了新的文献求助10
1分钟前
2分钟前
2分钟前
hzj发布了新的文献求助10
2分钟前
2分钟前
酷波er应助积极嚓茶采纳,获得30
2分钟前
高分求助中
Востребованный временем 2500
Production Logging: Theoretical and Interpretive Elements 2000
Agaricales of New Zealand 1: Pluteaceae - Entolomataceae 1500
Early Devonian echinoderms from Victoria (Rhombifera, Blastoidea and Ophiocistioidea) 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 1000
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 1000
Metal Additive Manufacturing for Propulsion Applications 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3367495
求助须知:如何正确求助?哪些是违规求助? 2987023
关于积分的说明 8725531
捐赠科研通 2669579
什么是DOI,文献DOI怎么找? 1462254
科研通“疑难数据库(出版商)”最低求助积分说明 676782
邀请新用户注册赠送积分活动 667952